Enlivex Therapeutics’ (ENLV) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a research note released on Tuesday,Benzinga reports. D. Boral Capital currently has a $13.00 price objective on the stock.

Separately, HC Wainwright raised their price target on shares of Enlivex Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, March 24th.

Enlivex Therapeutics Trading Down 2.4%

NASDAQ ENLV opened at $1.14 on Tuesday. Enlivex Therapeutics has a 1 year low of $0.81 and a 1 year high of $1.76. The firm has a market capitalization of $27.01 million, a price-to-earnings ratio of -1.73 and a beta of 0.79. The firm’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $1.06.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its earnings results on Friday, May 30th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. On average, equities research analysts forecast that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Enlivex Therapeutics

Several large investors have recently modified their holdings of ENLV. Two Sigma Securities LLC bought a new position in shares of Enlivex Therapeutics during the fourth quarter valued at $26,000. Jane Street Group LLC raised its stake in Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after buying an additional 67,886 shares during the last quarter. Renaissance Technologies LLC raised its stake in Enlivex Therapeutics by 112.6% during the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after buying an additional 84,203 shares during the last quarter. Finally, Millennium Management LLC bought a new position in Enlivex Therapeutics during the fourth quarter worth $742,000. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.